On September 28, 2018 ITUS Corporation (the "Company") (NASDAQ: ITUS), a biotechnology company focused on using the body’s immune system to fight cancer, reported that on October 1, 2018, the Company will officially change its name to Anixa Biosciences, Inc (Press release, Anixa Biosciences, SEP 28, 2018, View Source [SID1234530494]). Effective at the start of trading on October 1, 2018, the Company’s shares will trade on the NASDAQ Capital Market under the new name, and the new stock symbol will be "ANIX." The Company’s website will be accessible at www.anixa.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Amit Kumar, the Company’s CEO stated, "We are focused on making advances in the biotechnology field. We began in diagnostics with development of the Cchek platform for early detection of cancer and are expanding into cancer therapeutics as we develop our CAR-T therapy for ovarian cancer. We believe the name Anixa Biosciences more accurately reflects this focus and clearly identifies us as biotech company. The ITUS name is more reflective of our legacy operations."